Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy

Phase 3 Active not recruiting 190 enrolled The George Institute Chinese University of Hong Kong · collab Clinica Alemana de Santiago · collab Monash University · collab The Alfred · collab Universidad del Desarrollo · collab University of Sydney · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

STRONGER is an international, investigator initiated and conducted, pragmatic clinical trial to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults with long COVID neurological symptoms. The objective is to determine effectiveness of treatment with 40mg atorvastatin over 12 months on attenuating cognitive decline and neuroinflammatory biomarkers in adults with long COVID neurological symptoms. The study design is a prospective, randomised, open-label, blinded endpoint (PROBE) study of atorvastatin 40mg on top of standard care, in patients with long COVID neurological symptoms.

Timeline

Start: 2022-03-10
Primary completion: 2025-06-30
Completion: 2025-07-30

Publications

Delfino C, Carcel C, Lin X, Munoz-Venturelli P, Naismith SL, Woodward M, Peters R, Wijesuriya N, Law M, Harding IH, Wang X, Elliott J, Leder K, Hutchings O, Stecher X, Zoungas S, Anderson CS. STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER): study protocol for a randomised, open label clinical trial in patients with persistent neurological symptoms after COVID-19 infection. BMJ Open. 2025 Apr 14;15(4):e089382. doi: 10.1136/bmjopen-2024-089382.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	40 mg	—

Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy

Summary

Timeline

Publications

Drugs

Indications